stockrowWarby Parker Inc.
WRBY Healthcare Medical Instruments & Supplies
Warby Parker Inc.’s revenue for fiscal 2025 (year ended December 2025) was $871.9 million, up 13.0% from fiscal 2024.
- Revenue
- +10.4%
- EPS
- −20.0%
- Free cash flow
- −30.3%
Quarter to September 2026, against a year earlier
Follow WRBY
Alert me
Warby Parker Inc. (WRBY) Shares outstanding
Warby Parker Inc.'s shares outstanding at the end of fiscal 2025 was $125.1M, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $126.1M. Over the past ten years it has ranged from $52.4M (fiscal 2019) to $125.1M (fiscal 2025) — the current reading is the highest in ten years. Warby Parker Inc. ranks 15th of 47 Medical Instruments & Supplies companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $125.1M | 3.92% |
| FY2024 | $120.4M | 2.55% |
| FY2023 | $117.4M | 2.13% |
| FY2022 | $114.9M | 61.32% |
| FY2021 | $71.2M | 34.35% |
| FY2020 | $53.0M | 1.16% |
| FY2019 | $52.4M | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $126.1M | 0.32% |
| Jun 2026 | $125.7M | 0.15% |
| Mar 2026 | $125.6M | 0.36% |
| Dec 2025 | $125.1M | (0.25%) |
| 22 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| STVN Stevanato Group S.p.A. compare | $273.1M |
| XRAY DENTSPLY SIRONA Inc. compare | $199.2M |
| WRBY Warby Parker Inc. | $126.1M |
| PLSE Pulse Biosciences, Inc compare | $71.9M |
| KMTS Kestra Medical Technologies, Ltd. compare | $58.6M |
| ATRC AtriCure, Inc. compare | $49.8M |
| AZTA Azenta, Inc. compare | $45.3M |
| ICUI ICU Medical, Inc. compare | $25.1M |
| LMAT LeMaitre Vascular, Inc. compare | $23.1M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on WRBY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement